Revive Therapeutics Ltd (RVV)

Just to f**k with us :)

Why?

Canadian Investment Regulatory Organization Trade Resumption - RVVJune 8, 2026 8:45 AM
PR Newswire (Canada) VANCOUVER, BC, June 8, 2026 /CNW/ - Trading resumes in:Company: Revive Therapeutics Ltd.CSE Symbol: RVVAll Issues: NoResumption (ET): 9:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions Original: Canadian Investment Regulatory Organization Trade Resumption - RVV

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - RVVJune 8, 2026 8:47 AM
PR Newswire (Canada) VANCOUVER, BC, le 8 juin 2026 /CNW/ - Reprise des négociations pour:Société : Revive Therapeutics Ltd.Symbole CSE : RVVLes titres : NonReprise (HE) : 09 h 00L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises Original: L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - RVV

Canadian Investment Regulatory Organization Trading Halt - RVVJune 8, 2026 8:04 AM
PR Newswire (Canada) VANCOUVER, BC, June 8, 2026 /CNW/ - The following issues have been halted by CIRO:Company: Revive Therapeutics Ltd.CSE Symbol: RVVAll Issues: NoReason: Cease Trade OrderHalt Time (ET): 7:49 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions Original: Canadian Investment Regulatory Organization Trading Halt - RVV

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - RVVJune 8, 2026 8:06 AM
PR Newswire (Canada) VANCOUVER, BC, le 8 juin 2026 /CNW/ - L'OCRI a suspendu la négociation des titres suivants :Société : Revive Therapeutics Ltd.Symbole CSE : RVVLes titres : NonMotif : Interdiction d'opérations sur valeursHeure de la suspension (HE) : 07 h 49L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises Original: Suspension de la négociation par l'Organisme canadien de réglementation des investissements - RVV

Revive HAS:
active R&D
university collaboration
government-linked research
continuing IP expansion
real scientific mechanisms
For example:
collaboration with the University of Waterloo on new formulations
DRDC collaboration
actual patent grants
This materially increases legitimacy compared to pure promotional biotech shells.

Chance of Canadian news on Monday (US holiday)?

Chance of Canadian news on Monday (US holiday)?

Good morning and happy Wednesday Mike exclamation I’m sure you saw the news out this morning. It’s exciting to see and be a part of next steps and a more advanced stage for revive.

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical CountermeasuresMay 20, 2026 7:45 AM
ACCESS NewswireCompany to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpilingTORONTO, ON / ACCESS Newswire / May 20, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, today announced its strategic expansion plan for bucillamine across infectious disease, defence and biothreat-related applications.Revive believes bucillamine represents a differentiated strategic asset with potential relevance across multiple high-need areas, including infectious diseases, future pandemic preparedness, nerve-agent exposure, chemical threats, and broader government medical countermeasure programs. The Company's strategy is supported by three important pillars: its strengthened intellectual property portfolio, its ongoing research collaboration with Defence R&D Canada - Suffield Research Centre ("DRDC"), and bucillamine's established clinical history."Bucillamine is not a one-indication opportunity for Revive - we believe it has the potential to become a franchise drug candidate across infectious diseases, defence, biothreat preparedness and medical countermeasures," said Michael Frank, Chief Executive Officer of Revive. "With a granted Canadian patent covering bucillamine for infectious diseases, North American patent filings for nerve-agent exposure, an active research program with DRDC, and bucillamine's established clinical history, Revive is building a broader strategic platform around an asset we believe may be relevant to future pandemics, chemical threats and government preparedness initiatives. While additional preclinical work and regulatory development are required, we believe this strategy represents a significant opportunity to create long-term value from bucillamine beyond any single indication."Building a Bucillamine Franchise for Infectious Diseases, Defence and Biothreat PreparednessRevive intends to initiate additional preclinical studies to further evaluate bucillamine in infectious disease and defence-related indications, including potential applications connected to nerve-agent exposure, chemical threats, viral infections, and future pandemic preparedness. The Company also intends to pursue discussions with government agencies, defence organizations, and strategic partners to explore potential research collaborations, non-dilutive funding opportunities, procurement pathways, and future stockpiling programs.Revive believes this strategy is timely given the growing global focus on preparedness for pandemics, chemical threats, biological threats, and emergency medical countermeasures. Government stockpiling programs and preparedness mandates may represent important future opportunities for drug candidates that demonstrate relevant safety, efficacy, scalability, and regulatory readiness.Canadian Patent Grant Strengthens Bucillamine Position in Infectious DiseasesRevive recently announced the grant of Canadian Patent No. 3,172,170, entitled "Use of Bucillamine in the Treatment of Infectious Diseases." The patent was granted on March 10, 2026 and, according to the issued patent notice, expires on March 16, 2041.The patent covers methods and uses of bucillamine for the treatment or prevention of infectious diseases, including examples such as influenza and COVID-19. Revive believes this granted patent strengthens its long-term intellectual property position and supports future partnering, licensing, and development discussions involving bucillamine for infectious disease and pandemic-preparedness opportunities.North American Patent Filings Advance Bucillamine for Nerve-Agent ExposureRevive has also filed U.S. and Canadian national phase patent applications under PCT/CA2024/000008 for "Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent." The nerve-agent filings include U.S. application No. 19/518,001 and Canadian application No. 3,304,264.Revive believes these filings expand bucillamine's potential role as a medical countermeasure candidate and support the Company's broader strategy of evaluating bucillamine in defence, emergency-response, and biothreat-related applications.Bucillamine PotentialBucillamine is a thiol-based drug with a substantial clinical history, including more than 30 years of use in rheumatoid arthritis in Japan and South Korea. Revive believes bucillamine's antioxidant, anti-inflammatory, and thiol-donating properties may support its evaluation across multiple areas where oxidative stress, inflammation, and tissue injury are believed to play important roles.Revive has also previously advanced bucillamine through late-stage human clinical development, providing the Company with meaningful operational, regulatory, and clinical-development experience. Combined with its intellectual property portfolio and DRDC research collaboration, Revive believes bucillamine has the potential to become a broader platform opportunity in infectious diseases, defence, and medical countermeasures.Strategic Path ForwardRevive's bucillamine expansion strategy includes:Advancing additional preclinical studies in infectious disease, nerve-agent exposure, and other defence or biothreat-related applications;Strengthening the bucillamine intellectual property portfolio across infectious diseases, nerve-agent exposure, and related medical countermeasure opportunities;Pursuing government and defence partnerships to support research, development, and potential procurement pathways;Exploring potential stockpiling opportunities where bucillamine may align with government preparedness priorities; andPositioning bucillamine as a potential franchise asset for future pandemics, biothreats, chemical threats, and other high-need public-health or defence applications.Revive believes this expanded strategy has the potential to reposition bucillamine from a single-asset infectious disease program into a broader medical countermeasure platform. The Company intends to provide further updates as additional preclinical studies are initiated, DRDC findings become available for disclosure, and partnership discussions advance.About Revive Therapeutics Ltd.Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug-development efforts to take advantage of regulatory incentives that may be available for important unmet medical needs. The Company is currently exploring the use of bucillamine for infectious diseases, nerve agent exposure and long COVID, among other potential applications. For more information, visit www.ReviveThera.com.For more information, please contact:Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.comNeither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.Cautionary StatementThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information in this release includes, but is not limited to, statements regarding the potential therapeutic, commercial, regulatory, defence, public-health, or medical-countermeasure value of bucillamine; the Company's plans to initiate additional preclinical studies; the potential expansion of bucillamine into infectious diseases, nerve-agent exposure, chemical threats, biothreats, future pandemics, defence applications, or stockpiling programs; the potential for government partnerships, procurement opportunities, non-dilutive funding, or preparedness mandates; the potential value and scope of the Company's patent portfolio; the timing, completion, interpretation, authorization, or disclosure of DRDC study results; and the potential for bucillamine to become a franchise asset. Forward-looking information is based on Revive's current expectations, beliefs, and assumptions and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information. There can be no assurance that bucillamine will demonstrate safety or efficacy in any new indication, that preclinical studies will be successful, that DRDC final pathology results will be positive, that DRDC will authorize the release of any findings, that any government partnership, funding, procurement, or stockpiling opportunity will be secured, or that any regulatory approval or commercial opportunity will be achieved. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and Revive undertakes no obligation to update or revise any forward-looking information except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading "Risk Factors" in the Company's management's discussion and analysis for the three and six months ended December 31, 2025 ("MD&A"), dated February 25, 2026, which is available on the Company's profile at www.sedarplus.ca.SOURCE: Revive Therapeutics Ltd.View the original press release on ACCESS NewswireOriginal: Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

Good morning Mike. So true and a very real possibility of not only happening but likely of happening.

Companies that follow Canadian and US public stock rules and that are engaged in preparation for Chemical and Biological warfare when not long ago Syria was using Chemical weapons in the Middle east, we will have few if any clue ahead of time (IMO) when and if they are closing a massive deal to sell and stockpile an antigen Bucillamine for the US (at war with Iran) or Canada and NATO until the Military lets them, or the financials show huge profits.


The applications for Bucillamine are many and plenty-full. I was right long ago when I suggested it could be used to save lives fighting illegal chemical warfare agents. The issued Patent (one of possibly many world wide) is the proof.

Why isn't anything happening here?

Don’t know but good movement on US side.

Any movement on the Canadian side?

🚀 LFG

I think M Frank is waiting for the next market downturn to release news. You know, penny stocks can soar when major indices sell off.

Activity seems to be low key accumulation…

Possibly. With everything going on it would be nice to have more insight and perspective.

Something soon?

Nice little bump up today.

Likely due to there not being any official releases from Mikey on the status of the CDD trial.

We have no clue what inspired this latest jaunt to the 5s but I can say with certainty that its enjoyable...... while it la$t$.

Crazy how quiet it is on this board….??

Sure is quiet today.

My prediction was slightly off, down to 0.02. Actual 0.0271

Bucillamine holds significance in the context of nerve agent exposure due to its neuroprotective properties and potential therapeutic applications. Here are the key points highlighting its importance:
1. Mechanism of Action: Bucillamine acts as a potent antioxidant, which helps protect nerve cells from oxidative stress and damage caused by nerve agents. These agents, such as sarin and VX, disrupt neurotransmission, leading to severe neurological impairments.
2. GABA(A) Receptor Protection: Research indicates that Bucillamine may protect GABA(A) receptors from the harmful effects of nerve agents, which can lead to seizures and other neurological complications. This protective effect is critical in mitigating the neurotoxic consequences of nerve agent exposure.
3. Preclinical Studies: Bucillamine is currently being evaluated in preclinical studies funded by the Canadian Department of National Defence. These studies aim to assess its efficacy and safety in countering the effects of nerve agents, potentially paving the way for clinical trials and regulatory approvals.
4. Potential Medical Countermeasure: The compound's development as a medical countermeasure for nerve agent exposure positions it as a vital asset for military and emergency response teams. Its ability to be administered orally and its established safety profile (from use in treating other conditions, such as arthritis) make it an attractive candidate for rapid deployment in emergency situations.
5. Broader Implications: Beyond nerve agents, Bucillamine's properties may extend to other conditions involving oxidative stress and neuronal damage, such as traumatic brain injury and long COVID. This broadens its potential utility in various medical scenarios.

Overall, Bucillamine's potential to prevent or mitigate the neurological effects of nerve agents underscores its significance as a therapeutic strategy in biodefense and emergency medical response.

Key Reasons for Investment:

Imminent Scientific De-risking: Final results from the DRDC nerve-agent study are expected to be authorized for release soon, serving as a binary catalyst for the stock.
Asymmetric Upside: With a market cap of only $26M, there is potential for a move toward a $1.00 price target ($400M+ valuation) if the Company wins a defense contract and will align with standard industry multiples for companies holding exclusive government defense contracts.
Safe Harbor IP: Exclusivity until 2041 provides a long-term safety net for investors, ensuring that any breakthrough in stockpiling remains a monopoly for Revive.
At $0.06, the market is just beginning to price in the defense shift. For those entering now, the opportunity lies in the convergence of scientific validation and the growing global demand for chemical and biological preparedness.

Regulatory Pathways and Government Stockpiling

Because human efficacy trials for nerve agents are unethical, the FDA provides the “Animal Rule” pathway. This allows for approval based on animal data and established human safety profiles—a major advantage for Bucillamine given its decades of clinical history in Japan and South Korea.

Unlike traditional pharmaceuticals, MCMs are often purchased in bulk for National Strategic Stockpiles. Allied nations across the “Five Eyes” network allocate billions toward these programs. Securing even a pilot procurement contract could justify a valuation far beyond the company’s current levels.

Recent Developments
? Patent Grants and Filings (March 2026): Canadian Intellectual Property Office granted Patent No. 3,172,170 on March 10 for Bucillamine in infectious diseases (e.g., influenza, COVID-19), valid until March 16, 2041. On March 11, Revive filed North American patents for nerve agent exposure (U.S. No. 19/518,001; Canadian No. 3,304,264), strengthening its IP portfolio. 1 ↗ (https://revivethera.com) 7 ↗ (https://smallcappower.com/news/market-news/the-defense-playbook-why-revive-therapeutics-could-be-a-high-leverage-biotech-opportunity/) 9 ↗ (https://revivethera.com/news/) 13 ↗ (https://firstwordpharma.com/story/7133892)
? DRDC Nerve Agent Study Updates:
| Date | Key Update | Expected Completion |
|------|------------|---------------------|
| Oct 31, 2024 | Additional control study for optimal dosing; promising for FDA/Health Canada approvals. 4 ↗ (https://www.biospace.com/press-releases/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure) | End of 2024 |
| Jun 26, 2025 | Progressing well; potential Health Canada stockpiling in 2026. 8 ↗ (https://www.santelog.com/actualites-sante-nasdaq/revive-therapeutics-nears-completion-key-nerve-agent-countermeasure-study) 10 ↗ (https://www.globenewswire.com/news-release/2025/06/26/3105718/0/en/Revive-Therapeutics-Nears-Completion-of-Key-Nerve-Agent-Countermeasure-Study-with-Canadian-Department-of-National-Defence-Highlighting-Significant-Stockpiling-Opportunity.html) | Sep 2025 |
| Nov 21/Dec 15, 2025 | Ongoing; results pending DRDC authorization. 6 ↗ (https://www.globenewswire.com/news-release/2025/11/21/3192926/0/en/Revive-Therapeutics-Provides-Update-of-Key-Nerve-Agent-Countermeasure-Study.html) 3 ↗ (https://www.stocktitan.net/news/RVVTF/revive-therapeutics-provides-update-of-key-nerve-agent-167jih25wb35.html) | Jan 2026 |
| Mar 11, 2026 | Final findings pending; positive data could lead to human trials. 1 ↗ (https://revivethera.com) 2 ↗ (https://www.clinicaltrialvanguard.com/news/bucillamine-research-for-nerve-agent-exposure-revive-therapeutics-update/) | Jan 2026 (confirmed) |

The study, funded by Defence R&D Canada (DRDC) – Suffield Research Centre (Canadian Department of National Defence), evaluates Bucillamine's neuroprotective effects against agents like sarin and VX. 2 ↗ (https://www.clinicaltrialvanguard.com/news/bucillamine-research-for-nerve-agent-exposure-revive-therapeutics-update/) 3 ↗ (https://www.stocktitan.net/news/RVVTF/revive-therapeutics-provides-update-of-key-nerve-agent-167jih25wb35.html) 7 ↗ (https://smallcappower.com/news/market-news/the-defense-playbook-why-revive-therapeutics-could-be-a-high-leverage-biotech-opportunity/)

Future Direction and Success Potential
Revive anticipates Q1 2026 DRDC results, potentially unlocking human trials in H2 2026, FDA/Health Canada approvals, and stockpiling contracts amid geopolitical tensions. 2 ↗ (https://www.clinicaltrialvanguard.com/news/bucillamine-research-for-nerve-agent-exposure-revive-therapeutics-update/) 5 ↗ (https://www.marketscreener.com/news/revive-therapeutics-investor-deck-rvv-deck-march-2026-ce7e5edadc8cf22c) 8 ↗ (https://www.santelog.com/actualites-sante-nasdaq/revive-therapeutics-nears-completion-key-nerve-agent-countermeasure-study) CEO Michael Frank highlighted Bucillamine's oral administration and safety profile (used for arthritis in Japan/South Korea for 30+ years) as advantages for military/first responders. 8 ↗ (https://www.santelog.com/actualites-sante-nasdaq/revive-therapeutics-nears-completion-key-nerve-agent-countermeasure-study)

Who would have thunk yesterday morning RNWF now AMFN would be a stronger hold today than Rvvtf. Mind blown! Riding free shares in both so pretty pleased!

Why the drop, any bad news

Wished I had paid 0.01 and sold at 0.05 no funds

Anyone buy at 0.01 and sell at 0.05 , make $160,000 usd

Will probably go to 0.02 then higher or drop a lot, 1,000,000% speculating. Imagine buying 4,000,000 @ 0.01 and sell at 0.05: anyone buy

We broke our morning ceiling of .0505....fun ride!

Strong Volume Right Out of the Gate

Volume already: ~1.5M shares

That’s BIG for RVVTF this early

👉 Confirms:

Todays morning indicates solid active participation and deep accumulation. IMHO...this is not a dead bounce.
Bullish continuation trigger is if we move up to .0505 break and hold. If this happens, the next move likely is the .060 test. .0043 is support. Good luck everyone, as far as I can tell, we are in heavy accumulation.

Price prediction

Interesting when I googled fda and patent. can take decade for approvals fda. patent does not speed things up. fda is safety

We need a good ole fashion Mikey run.  Lfg

600%+⬆ from recent lows............interesting!

Several days

Seems to be making 52 week high new

Opened higher and then collapses and now moving fast

Never owned

Probably go to 0.02 tomorrow and then a few days higher or zero, close to , 1,000,000% pure speculating, thinking $2 $2.50 down the road 1,000,000% pure speculating

I say 0.02 going forward then higher or drop further. 1,000,000% speculating

Well based on the fact that the most recent Pr said, "shortly", instead of an actual date, we can only that hope this break in trend means it will actually happen this time around. lol

I’ve been a shareholder of Revive since mid 2020 so I’ve seen how Revive (Michael Frank) tends to structure it’s Press Releases. Michael Frank is a horrible CEO. I’ve had email interactions with him in 2023 letting him know my disappointment with Revive’s mismanagement over their Bucillamine Phase 3 COVID-19 trial. He actually told me then that i should go talk/argue with the FDA about the difficulty with getting Bucillamine approved. I told him that a poorly designed clinical trial wasn’t the FDA’s fault and the fault for that was on Revive’s management.

Hopefully, things will be different this time with the DRDC taking the lead on the research study.

By the way, i emailed him this before i posted it here. ;) (asking him - "I see a pattern, do you?")
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177384308

Would have to agree with your assessment.....for now at least.

I do however won't complain about the 400%+ gain from the 008$.

Would have to agree with your assessment.....for now at least.

I do however won't complain about the 400%+ gain from the 008$.